amdoxovir

Amdoxovir is an investigational small molecule antiretroviral drug classified as a nucleoside reverse transcriptase inhibitor (NRTI). It is a guanosine analogue prodrug that is metabolized intracellularly to dioxolane guanine (DXG), which then forms DXG-triphosphate—the active moiety responsible for antiviral activity. Amdoxovir inhibits the RNA-directed DNA polymerase (reverse transcriptase) of HIV-1 and has demonstrated in vitro activity against both HIV-1 and hepatitis B virus (HBV). The drug was discovered by Raymond F. Schinazi at Emory University and C.K. Chu at the University of Georgia and was developed by RFS Pharma. Clinical development reached Phase II for HIV infection; however, trials were discontinued or terminated before approval[1][2][3][5][7].

Other names

amdoxovirDAPDbeta-D-2,6-diaminopurine-dioxolane